A Phase 4 interventional study of Infanrix™ hexa in Hepatitis B, Tetanus and Poliomyelitis, sponsored by GlaxoSmithKline. Completed at 3 sites in Canada. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-27.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Hepatitis B.
Among the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B, this one is the 12th largest by enrollment, is one of 3 that started in 2008, is one of 6 in phase 4, and was the 7th registered.
1,048 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.
Browse Hepatitis B studies →None of the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B is open now. The open studies under Hepatitis B, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2008.
This study's enrollment of 224 is above the median of 145 across 757 interventional studies indexed under Hepatitis B.
Median enrollment 417 across the 16 interventional studies. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
144 studies in Hepatitis B by GlaxoSmithKline: 2 open now, 6 under way, none of them phase 3. Of 136 finished, 69 (51%) have results posted.
Among the 144 studies in Hepatitis B by GlaxoSmithKline, this one is the 70th largest by enrollment of the 137 interventional ones that give a count, is one of 10 that started in 2008, is one of 36 in phase 4, and was the 79th registered.
GlaxoSmithKline’s Hepatitis B studies by the year they started, since 1992.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 144 in Hepatitis B:
This tab as a report to print or save as PDF → With an account.
This study will evaluate GSK Biologicals' DTPa-HBV-IPV/Hib vaccine given as a three-dose primary vaccination course at 2, 4 and 6 months of age, in terms of safety and immunogenicity in different population of infants residing in Canada.
This protocol posting has been updated following Protocol amendment 1 (19-MAY-2010).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Infanrix™ hexa
Biological: Infanrix™ hexa
Intramuscular, three doses
Also known as: DTPa-HBV-IPV/Hib
Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (Anti-PRP)
A seroprotected subject was a subject whose anti-PRP antibody concentration was greater or equal to (≥) 0.15 microgram per milliliter (µg/mL).
Time frame: One month after (POST) Dose 3.
Number of Subjects With Anti-PRP Antibody Concentrations ≥1µg/mL
For this assay, 1 μg/mL was considered as the seropositivity cut-off.
Time frame: One month after (POST) Dose 3.
Anti-PRP Antibody Concentrations
Anti-PRP antibody concentrations were presented as Geometric mean Concentrations (GMC), expressed as micrograms per milliliter (μg/mL).
Time frame: One month after (POST) Dose 3.
Number of Seroprotected Subjects Against Hepatitis B (Anti-HBs)
A seroprotected subject was a subject with anti-HBs antibody concentrations ≥ 10 milli-International Units ler milliliter (mIU/mL). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following partial or complete retesting/reanalysis. Some of the available blood samples initially tested with ELISA were re-tested using the new assay, CLIA.
Time frame: One month after (POST) Dose 3.
Number of Subjects With Anti-HBs Antibody Concentrations ≥100 mIU/mL
The testing was done using the Enzyme-Linked Immunosorbent assay (ELISA) assay.
Time frame: One month after (POST) Dose 3.
Anti-HBs Antibody Concentrations
Anti-HBs antibody concentrations were assessed by Enzyme-Linked Immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs).
Time frame: One month after (POST) Dose 3.
Number of Subjects With Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Time frame: During the 31 day (Days 0-30) post vaccination
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the entire study period up to Last subject last visit on 03/12/2013
Study started on 23-Sep-2008 and enrolled 224 subjects from Canada.
| Milestone | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group |
|---|---|---|
| Started | 112 | 112 |
| Completed | 105 | 112 |
| Not completed | 7 | 0 |
| Withdrew: Migrated/moved from study area | 1 | 0 |
| Withdrew: Lost to follow-up-incomplete vaccination | 3 | 0 |
| Withdrew: Lost to follow-up-complete vaccination | 1 | 0 |
| Withdrew: Protocol violation | 2 | 0 |
A seroprotected subject was a subject whose anti-PRP antibody concentration was greater or equal to (≥) 0.15 microgram per milliliter (µg/mL).
| Subjects | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group |
|---|---|---|
| Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (Anti-PRP) | 92 | 106 |
For this assay, 1 μg/mL was considered as the seropositivity cut-off.
| Subjects | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group |
|---|---|---|
| Number of Subjects With Anti-PRP Antibody Concentrations ≥1µg/mL | 83 | 91 |
Anti-PRP antibody concentrations were presented as Geometric mean Concentrations (GMC), expressed as micrograms per milliliter (μg/mL).
| µg/mL | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group |
|---|---|---|
| Anti-PRP Antibody Concentrations | 6.123 (4.498 to 8.334) | 3.51 (2.745 to 4.488) |
A seroprotected subject was a subject with anti-HBs antibody concentrations ≥ 10 milli-International Units ler milliliter (mIU/mL). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following partial or complete retesting/reanalysis. Some of the available blood samples initially tested with ELISA were re-tested using the new assay, CLIA.
| Subjects | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group |
|---|---|---|
| Number of Seroprotected Subjects Against Hepatitis B (Anti-HBs) | 91 | 103 |
The testing was done using the Enzyme-Linked Immunosorbent assay (ELISA) assay.
| Subjects | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group |
|---|---|---|
| Number of Subjects With Anti-HBs Antibody Concentrations ≥100 mIU/mL | 89 | 100 |
Anti-HBs antibody concentrations were assessed by Enzyme-Linked Immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs).
| mIU/mL | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group |
|---|---|---|
| Anti-HBs Antibody Concentrations | 1797.9 (1375.1 to 2350.7) | 1544.4 (1210.4 to 1970.5) |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
| Subjects | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group |
|---|---|---|
| Number of Subjects With Unsolicited Adverse Events (AEs) | 26 | 19 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Subjects | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 6 | 0 |
Collected over Unsolicited AEs during the 31-day post-vaccination period, SAEs during the entire period up to Last subject last visit on 03/12/2013.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infanrix Hexa Aboriginal Group | — | 6/112 (5.4%) | 6/112 (5.4%) |
| Infanrix Hexa Non-Aboriginal Group | — | 0/112 (0%) | 0/112 (0%) |
| Event | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group |
|---|---|---|
| ConvulsionNervous system disorders | 2/112 | 0/112 |
| Febrile convulsionNervous system disorders | 1/112 | 0/112 |
| PyrexiaGeneral disorders | 1/112 | 0/112 |
| BronchiolitisInfections and infestations | 1/112 | 0/112 |
| Pneumonia bacterialInfections and infestations | 1/112 | 0/112 |
| Respiratory syncytial virus infectionInfections and infestations | 1/112 | 0/112 |
| Event | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group |
|---|---|---|
| PyrexiaGeneral disorders | 6/112 | 0/112 |
| Age, Continuous(Weeks) | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group | Total |
|---|---|---|---|
| Mean | 9.3 ± 1.38 | 9.2 ± 1.3 | 9.25 ± 1.34 |
| Sex: Female, Male(Participants) | Infanrix Hexa Aboriginal Group | Infanrix Hexa Non-Aboriginal Group | Total |
|---|---|---|---|
| Female | 62 | 52 | 114 |
| Male | 50 | 60 | 110 |
Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Sep 2008 to primary completion in Mar 2013, 53 months.
Results were first posted in Nov 2016, 3 years 8 months after primary completion. A results delay was requested in Apr 2013.
Of 63 phase 4 interventional studies under Hepatitis B, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's 53 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine